赵伟杰

个人信息Personal Information

教授

博士生导师

硕士生导师

性别:男

毕业院校:日本富山医科药科大学

学位:博士

所在单位:化工学院

学科:药物化学. 药物分析学

办公地点:西部新校区G-302室(制药科学与技术学院)

联系方式:84986195

电子邮箱:zyzhao@dlut.edu.cn

扫描关注

论文成果

当前位置: 中文主页 >> 科学研究 >> 论文成果

用于2型糖尿病研究的3D多器官芯片

点击次数:

发表时间:2019-01-01

发表刊物:生物化学与生物物理进展

卷号:46

期号:06

页面范围:620-630

ISSN号:1000-3282

摘要:Type 2 diabetes is a systematic metabolic disease that involves complex interplay of multiple organs, of which adipose tissue and pancreatic islet are two key organs related to its pathogenesis. In this paper, models of fat 3D organ chip, islet 3D organ chip and their combination were established, which can be used to study the pathogenesis and to assess the mechanism of hypoglycemic agents for treatment of type 2 diabetes. A two-channel composite microfluidic chip was designed to study the effects of lipopolysaccharide (LPS) first on fat cells in one chip chamber and on islet cell in a seperate chip culture chamber. The chip channel was continuously perfused to simulate constantly changes in contents of the body fluid. The secretion of inflammatory factors such as adiponectin (ADP), interleukin-6 (IL-6) and interleukin-1 beta (IL-1 beta) from adipocytes and islet cells, the insulin secretion from islet cells, and islet cell survival rate in medium flashed with LPS or LPS / liraglutide were compared with those from cells flashed with the control medium. The results showed that LPS decreased ADP production from fat 3D organ chip, in islet 3D organ chip, and in fat/islet 3D double organ chip, LPS promoted IL-1 beta and IL-6 production from fat 3D organ chip and 3D fat/islet double organ chip, but not from islet 3D organ chip. Liraglutide could improve the production of ADP, and decreased IL-1 beta, IL-6 from fat 3D organ chip and fat/ islet 3D double organ chip, but no effects on islet 3D organ chip. LPS and liraglutide separate or in combination had no effect on insulin production from islet 3D organ chip, but LPS decreased insulin production from fat/islet 3D double organ chip, liraglutide improved the decreased insulin production from fat/islet double organ chip due to LPS. The platform for the combined application of the fat organ and the islet organ based on the microfluidic chip can be applied to the multi-organ disease reaction caused by the interaction between different tissues and is expected to be a powerful tool for drug evaluation of systemic metabolic diseases such as type 2 diabetes.

备注:新增回溯数据